KP
RETA

Keel Point’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Keel Point’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,446
Closed -$1.31M – 331
2023
Q1 		$1.31M Sell
14,446
-43,333
-75% -$2.54M 0.19% 91
2022
Q4 		$2.2M Hold
57,779
– – 0.34% 63
2022
Q3 		$1.45M Hold
57,779
– – 0.25% 75
2022
Q2 		$1.25M Buy
57,779
+10,207
+21% +$305K 0.19% 88
2022
Q1 		$1.56M Buy
47,572
+15
+0% +$445 0.23% 80
2021
Q4 		$1.25M Sell
47,557
-49,517
-51% -$3.83M 0.14% 95
2021
Q3 		$9.77M Sell
97,074
-649
-0.7% -$76.1K 1.26% 16
2021
Q2 		$13.8M Sell
97,723
-9,736
-9% -$1.1M 1.54% 12
2021
Q1 		$10.7M Sell
107,459
-5,690
-5% -$664K 1.04% 18
2020
Q4 		$14M Sell
113,149
-7,112
-6% -$935K 1.25% 16
2020
Q3 		$11.7M Buy
120,261
+3,114
+3% +$389K 1.06% 20
2020
Q2 		$18.3M Buy
117,147
+2,490
+2% +$379K 1.89% 15
2020
Q1 		$16.6M Buy
114,657
+1,344
+1% +$259K 2.14% 11
2019
Q4 		$23.2M Buy
113,313
+22,552
+25% +$4.11M 2.52% 8
2019
Q3 		$7.29M Buy
90,761
+9,810
+12% +$832K 0.89% 23
2019
Q2 		$7.64M Hold
80,951
– – 0.87% 23
2019
Q1 		$6.92M Sell
80,951
-1,900
-2% -$158K 0.8% 26
2018
Q4 		$4.65M Buy
82,851
+3,780
+5% +$231K 0.63% 27
2018
Q3 		$6.46M Hold
79,071
– – 0.8% 27
2018
Q2 		$2.77M Hold
79,071
– – 0.37% 29
2018
Q1 		$1.62M Hold
79,071
– – 0.22% 37
2017
Q4 		$2.24M Hold
79,071
– – 0.31% 32
2017
Q3 		$2.46M Hold
79,071
– – 0.37% 32
2017
Q2 		$2.5M Hold
79,071
– – 0.5% 30
2017
Q1 		$1.79M Buy
79,071
+24,639
+45% +$609K 0.36% 36
2016
Q4 		$1.19M Hold
54,432
– – 0.27% 41
2016
Q3 		$1.44M Buy
54,432
+4,254
+8% +$84.4K 0.55% 27
2016
Q2 		$991K Buy
+50,178
New +$975K 0.43% 39

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Keel Point's RETA Position: Q2 2023 in Review

Keel Point sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 14,446 shares — an estimated $1.31M sold.

Keel Point first reported a position in RETA in Q2 2016 and held it in 28 quarters. The position peaked at $23.2M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Keel Point reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Keel Point sold 14,446 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.31M.
  • Keel Point first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 28 quarters.
  • Keel Point's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $23.2M in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Keel Point's 13F filing for Q2 2023, filed 12 Jul 2023.